ClinicalTrials.gg
CompletedNCT00578305SCOREUpdated Apr 10, 2015Results posted

A Study of Rituximab (MabThera®/Rituxan®) in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate

A Phase 3 interventional study of Rituximab and Placebo in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 60 sites in 19 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2015-04-10.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
185
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 63 studies testing rituximab in Arthritis, Rheumatoid — 5 open to participants now, 6 under way, 1 of them phase 3. Rituximab · Arthritis, Rheumatoid.

Enrollment
28th of 63
185 · median 159
Started
2007
with 10 others
Phase 3
27 of 63
1 open now
Registered
21st of 63
by date
Lead sponsor
20 of 63
Hoffmann-La Roche

Among the 63 studies testing rituximab in Arthritis, Rheumatoid, this one is the 28th largest by enrollment, is one of 11 that started in 2007, is one of 27 in phase 3, and was the 21st registered.

Arthritis, Rheumatoid

3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 63 studies testing rituximab in Arthritis, Rheumatoid are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing rituximab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This 3 arm study assessed the efficacy of rituximab (MabThera®/Rituxan®) in the prevention of progression of structural joint damage in participants with active rheumatoid arthritis who had an inadequate clinical response to methotrexate. Participants were randomized to receive rituximab 500 mg intravenously (iv), rituximab 1000 mg iv, or placebo iv on days 1 and 15 every 24 weeks in the main study; all participants received concomitant methotrexate at a stable dose of 12.5-25 mg/week throughout the study. Further courses of rituximab were provided to eligible participants. Structural joint damage was assessed by magnetic resonance imaging (MRI) at baseline and at intervals during the study.

Read the detailed description

There were 3 phases in the study: A 52 week long main study, a study extension phase, and a 48 week long safety follow-up phase.

The first course of treatment with placebo or rituximab was initiated on Day 1 of the 52 week long main study. A second course of treatment was initiated after Week 24, if the participant met eligibility criteria. After Week 52, eligible participants received further treatment courses at intervals ≥ 6 months in the study extension phase. No treatments were administered in the safety follow-up phase.

Participants had to meet the following eligibility criteria to receive rituximab in the study extension phase.

  • Minimum of 24 weeks had passed since the first infusion of the last course of study medication.
  • C-reactive protein-based Disease Activity Score 28 (DAS28-CRP) ≥ 2.6.
  • Absolute neutrophil count not below 1.5 x 103/μL.
  • Patient had not developed contraindications for receiving rituximab, such as:

    1. Any new or uncontrolled concomitant disease such as, but not limited to, cardiovascular disease, nervous system, pulmonary, renal, hepatic, endocrine or gastrointestinal disorders.
    2. Primary or secondary immunodeficiency (history of, or currently active), including known history of HIV infection.
    3. Known active infection of any kind (excluding fungal infections of nail beds), or any major episode of infection requiring hospitalization, or treatment with iv anti-infectives within 4 weeks prior to infusion or completion of oral anti-infectives within 2 weeks prior to infusion.
  • Patient was not pregnant or breast feeding.
  • Patients who entered the study and were found to be hepatitis B surface antigen (HBsAg) negative, hepatitis B core antibody (HBcAb) positive, were to be negative for hepatitis B viral DNA (\< 29 IU/mL) and were to have aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN) results within the last 12 weeks.
03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, 18-80 years of age.
  • Active rheumatoid arthritis for ≥ 3 months and ≤ 10 years.
  • Evidence of erosive disease and/or clinical synovitis in a signal joint.
  • Inadequate response to 12.5-25 mg/week methotrexate for ≥ 12 weeks.

Exclusion criteria

Exclusion Criteria:

  • Rheumatic disease or inflammatory joint disease other than rheumatoid arthritis. - Any surgical procedure within 12 weeks prior to baseline.
  • Previous treatment with a biologic agent or with a B cell modulating or cell depleting therapy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
185 participants (actual)

Study arms

  • Experimental
    Rituximab 500 mg

    Participants received rituximab 500 mg iv on Day 1 and Day 15 of the main study. Participants received a second course of treatment on Day 1 and Day 15 after Week 24 of the main study, if they met eligibility criteria (see the Detailed Description). Participants received further treatment courses on Day 1 and Day 15 at intervals of ≥ 6 months after Week 52 in the study extension phase, if they met eligibility criteria (see the Detailed Description). Throughout the study, participants received methylprednisolone 100 mg iv prior to infusion of the investigational drug, methotrexate 7.5 to 25 mg/week orally or parenterally, and folic acid or folate ≥ 5 mg/week orally.

    Biological: Rituximab · Drug: Methylprednisolone · Drug: Methotrexate · Drug: Folic acid or folate

  • Experimental
    Rituximab 1000 mg

    Participants received rituximab 1000 mg iv on Day 1 and Day 15 of the main study. Participants received a second course of treatment on Day 1 and Day 15 after Week 24 of the main study, if they met eligibility criteria (see the Detailed Description). Participants received further treatment courses on Day 1 and Day 15 at intervals of ≥ 6 months after Week 52 in the study extension phase, if they met eligibility criteria (see the Detailed Description). Throughout the study, participants received methylprednisolone 100 mg iv prior to infusion of the investigational drug, methotrexate 7.5 to 25 mg/week orally or parenterally, and folic acid or folate ≥ 5 mg/week orally.

    Biological: Rituximab · Drug: Methylprednisolone · Drug: Methotrexate · Drug: Folic acid or folate

  • Placebo comparator
    Placebo

    Participants received placebo intravenously (iv) on Day 1 and Day 15 of the main study. Participants received a second course of treatment on Day 1 and Day 15 after Week 24 of the main study, if they met eligibility criteria (see the Detailed Description). Participants were switched to receive rituximab 1000 mg iv on Day 1 and Day 15 at intervals of ≥ 6 months after Week 52 in the study extension phase, if they met eligibility criteria (see the Detailed Description). Throughout the study, participants received methylprednisolone 100 mg iv prior to infusion of the investigational drug, methotrexate 7.5 to 25 mg/week orally or parenterally, and folic acid or folate ≥ 5 mg/week orally.

    Drug: Placebo · Drug: Methylprednisolone · Drug: Methotrexate · Drug: Folic acid or folate

Interventions

  • BiologicalRituximab

    Rituximab was supplied as a sterile liquid for iv administration.

    Also known as: MabThera®, Rituxan®

  • DrugPlacebo

    Placebo was supplied as a sterile liquid in single-use vials for iv administration.

  • DrugFolic acid or folate
06

What researchers measure

Primary outcomes

  1. Change in Magnetic Resonance Imaging (MRI) Erosion Score From Baseline to Week 24

    The erosion score was determined according to the Outcome Measures in Rheumatology (OMERACT) rheumatoid arthritis MRI scoring (RAMRIS) system in magnetic resonance images with and without gadolinium of 15 anatomical locations in each wrist and 10 locations in each hand in the hand and wrist with the most arthritic activity. If there was no difference in disease activity between the hands, the dominant hand was used. Images were assessed by 2 experienced blinded musculoskeletal radiologists. Each location was scored in 0.5 increments from 0 to 10 with each integer unit increment representing a 10% loss of articular bone using the following scale. 0.0=normal, no erosion; 0.5=1-5% erosion; 1.0=6-10% erosion; 1.5=11-15% erosion; 2.0=16-20% erosion; etc, up to 10.0=96-100% erosion. The individual scores were summed and normalized to a range of 0 to 100 with a higher score indicating more erosion. A negative change score indicates improvement.

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Change in Magnetic Resonance Imaging (MRI) Erosion Score From Baseline to Weeks 12 and 52

    The erosion score was determined according to the Outcome Measures in Rheumatology (OMERACT) rheumatoid arthritis MRI scoring (RAMRIS) system in magnetic resonance images with and without gadolinium of 15 anatomical locations in each wrist and 10 locations in each hand in the hand and wrist with the most arthritic activity. If there was no difference in disease activity between the hands, the dominant hand was used. Images were assessed by 2 experienced blinded musculoskeletal radiologists. Each location was scored in 0.5 increments from 0 to 10 with each integer unit increment representing a 10% loss of articular bone using the following scale. 0.0=normal, no erosion; 0.5=1-5% erosion; 1.0=6-10% erosion; 1.5=11-15% erosion; 2.0=16-20% erosion; etc, up to 10.0=96-100% erosion. The individual scores were summed and normalized to a range of 0 to 100 with a higher score indicating more erosion. A negative change score indicates improvement.

    Time frame: Baseline to Week 52

  2. Change in Magnetic Resonance Imaging (MRI) Synovitis Score From Baseline to Weeks 12, 24, and Week 52

    The synovitis score was determined according to the Outcome Measures in Rheumatology (OMERACT) rheumatoid arthritis MRI scoring (RAMRIS) system in magnetic resonance images of 3 wrist regions and 5 metacarpophalangeal joints in the hand and wrist with the most arthritic activity. If there was no difference in disease activity between the hands, the dominant hand was used. Images were assessed by 2 experienced blinded musculoskeletal radiologists. Each location was scored in 0.5 increments from 0 to 3 with each integer unit increment representing a 33% enhancement of the maximum volume of enhancing tissue in the synovial compartment using the following scale: 0.0=normal, no synovitis; 0.5=1-17% estimated volume of enhancement; 1.0=18-33%; 1.5=34-50%; 2.0=51-67%; 2.5=68-83%; 3.0=84-100% estimated volume of enhancement. The individual scores were summed and normalized to a range of 0 to 100 with a higher score indicating more synovitis. A negative change score indicates improvement.

    Time frame: Baseline to Week 52

  3. Change in Magnetic Resonance Imaging (MRI) Osteitis Score From Baseline to Weeks 12, 24, and Week 52

    The osteitis score was determined according to the Outcome Measures in Rheumatology (OMERACT) rheumatoid arthritis MRI scoring (RAMRIS) system in magnetic resonance images of 15 anatomical locations in each wrist and 10 locations in each hand in the hand and wrist with the most arthritic activity. If there was no difference in disease activity between the hands, the dominant hand was used. Each location was scored in 0.5 increments from 0 to 3 with each integer unit increment representing a 33% increase in the volume of the peripheral 1 cm of original (eroded + residual) articular bone using the following scale: 0.0=normal, no osteitis; 0.5=1-17% involvement of original articular bone; 1.0=18-33%; 1.5=34-50%; 2.0=51-67%; 2.5=68-83%; 3.0=84-100% involvement of original articular bone. The individual scores were summed and normalized to a range of 0 to 100 with a higher score indicating more synovitis. A negative change score indicates improvement.

    Time frame: Baseline to Week 52

  4. Percentage of Participants With no Newly Eroded Joints at Weeks 24 and 52

    No newly eroded joints was defined as no new erosions in joints which were scored 0 at baseline. The erosion score was determined according to the Outcome Measures in Rheumatology (OMERACT) rheumatoid arthritis MRI scoring (RAMRIS) system in magnetic resonance images with and without gadolinium of 15 anatomical locations in each wrist and 10 locations in each hand in the hand and wrist with the most arthritic activity. If there was no difference in disease activity between the hands, the dominant hand was used. Images were assessed by 2 experienced blinded musculoskeletal radiologists. Each location was scored in 0.5 increments from 0 to 10 with each integer unit increment representing a 10% loss of articular bone using the following scale. 0.0=normal, no erosion; 0.5=1-5% erosion; 1.0=6-10% erosion; 1.5=11-15% erosion; 2.0=16-20% erosion; etc, up to 10.0=96-100% erosion.

    Time frame: Baseline to Week 52

  5. Percentage of Participants With no Progression/no Worsening in Bone Erosion at Weeks 24 and 52

    There were 2 definitions of no progression/no worsening in bone erosion. A participant met the criterion for definition 1 when there was a change in the magnetic resonance imaging erosion score ≤ 0. A participant met the criteria for definition 2 when there was either (1) no change from Baseline in the MRI erosion score, (2) an increase in erosion score and the size of the increase in score was smaller than the smallest detectable change, or (3) a drop in the erosion score. The erosion score was determined according to the Outcome Measures in Rheumatology (OMERACT) rheumatoid arthritis MRI scoring (RAMRIS) system in magnetic resonance images with and without gadolinium of 15 anatomical locations in each wrist and 10 locations in each hand in the hand and wrist with the most arthritic activity. If there was no difference in disease activity between the hands, the dominant hand was used. Images were assessed by 2 experienced blinded musculoskeletal radiologists.

    Time frame: Baseline to Week 52

  6. Percentage of Participants With Improvement in Synovitis at Weeks 24 and 52

    There were 2 definitions of improvement in synovitis. A participant met the criterion for definition 1 when there was a drop in the magnetic resonance imaging synovitis score from Baseline \> 0.5. A participant met the criterion for definition 2 when there was a drop in the magnetic resonance imaging synovitis score from Baseline \> than the smallest detectable change. The synovitis score was determined according to the Outcome Measures in Rheumatology (OMERACT) rheumatoid arthritis MRI (RAMRIS) scoring system in magnetic resonance images with and without gadolinium of 15 anatomical locations in each wrist and 10 locations in each hand in the hand and wrist with the most arthritic activity. If there was no difference in disease activity between the hands, the dominant hand was used. Images were assessed by 2 experienced blinded musculoskeletal radiologists.

    Time frame: Baseline to Week 52

  7. Percentage of Participants With Improvement in Osteitis at Weeks 24 and 52

    There were 2 definitions of improvement in osteitis. A participant met the criterion for definition 1 when there was a drop in the magnetic resonance imaging osteitis score from Baseline \> 0.5. A participant met the criterion for definition 2 when there was a drop in the magnetic resonance imaging osteitis score from Baseline \> than the smallest detectable change. The osteitis score was determined according to the Outcome Measures in Rheumatology (OMERACT) rheumatoid arthritis MRI (RAMRIS) scoring system in magnetic resonance images with and without gadolinium of 15 anatomical locations in each wrist and 10 locations in each hand in the hand and wrist with the most arthritic activity. If there was no difference in disease activity between the hands, the dominant hand was used. Images were assessed by 2 experienced blinded musculoskeletal radiologists.

    Time frame: Baseline to Week 52

  8. Change From Baseline in the Disease Activity Score 28 (DAS28) at Weeks 24 and 52

    The DAS28 is a combined index for measuring disease activity in rheumatic arthritis (RA) and includes swollen and tender joint counts, C-reactive protein level (CRP), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(CRO)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints, GH = a participant's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity \[symptom-free and no arthritis symptoms\], right end = maximum disease activity \[maximum arthritis disease activity\]). The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. A negative change score indicates improvement.

    Time frame: Baseline to Week 52

  9. Percentage of Participants With European League Against Rheumatism (EULAR) Good, Moderate, or no Response at Weeks 24 and 52

    Change of the DAS28 score from Baseline was used to determine the EULAR responses. For a post-Baseline score ≤ 3.2, a change from Baseline of \< -1.2 was a good response, \< -0.6 to ≥ -1.2 was a moderate response, and ≥ -0.6 was no response. For a post-Baseline score \> 3.2 to ≤ 5.1, a change from Baseline of \< -0.6 was a moderate response and ≥ -0.6 was no response. For a post-Baseline score \> 5.1, a change from Baseline \< -1.2 was a moderate response and ≥ -1.2 was no response. A good response could not be achieved for post-Baseline scores \> 3.2. DAS28=(0.56×√(TJC28))+(0.28×√(SJC28))+(0.7×log(CRP))+(0.014×GH), where TJC28=tender joint count (JC) and SJC28=swollen JC (28 joints), GH=a participant's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end=no disease activity, right end=maximum disease activity), and CRP=C-reactive protein level. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.

    Time frame: Baseline to Week 52

  10. Percentage of Participants With Low Disease Activity (Disease Activity Score 28 [DAS28] ≤ 3.2) at Weeks 24 and 52

    The percentage of participants who had low rheumatic arthritis disease activity at Weeks 24 and 52, as measured by a DAS28 score ≤ 3.2, is reported. DAS28 is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(CRO)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints, GH = a participant's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity \[symptom-free and no arthritis symptoms\], right end = maximum disease activity \[maximum arthritis disease activity\]), and CRP = C-reactive protein level. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.

    Time frame: Baseline to Week 52

  11. Percentage of Participants in Remission Response (Disease Activity Score 28 [DAS28] < 2.6) at Weeks 24 and 52

    The percentage of participants in remission of their rheumatic arthritis at Weeks 24 and 52, as measured by a DAS28 score \< 2.6, is reported. DAS28 is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(CRO)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints, GH = a participant's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity \[symptom-free and no arthritis symptoms\], right end = maximum disease activity \[maximum arthritis disease activity\]), and CRP = C-reactive protein level. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.

    Time frame: Baseline to Week 52

  12. Percentage of Participants With an Improvement of at Least 20%, 50%, or 70% in the American College of Rheumatology (ACR) Score (ACR20/50/70) From Baseline at Weeks 24 and 52

    Improvement must be seen in tender and swollen joint counts (28 assessed joints; Joints were evaluated and classified as swollen or not swollen and tender or not tender based on pressure and joint manipulation upon physical examination) and in at least 3

    Time frame: Baseline to Week 52

  13. Percentage of Participants Achieving a Major Clinical Response at Week 52

    A major clinical response was defined as an improvement of at least 70% in the American College of Rheumatology score from Baseline at Week 52. Improvement must be seen in tender and swollen joint counts (28 assessed joints) and in at least 3 of the following 5 parameters: Separate participant and physician assessments of participant disease activity in the previous 24 hours on a visual analog scale (VAS, the extreme left end of the line "no disease activity" \[symptom-free and no arthritis symptoms\] and the extreme right end "maximum disease activity"); participant assessment of pain in previous the 24 hours on a VAS (extreme left end of the line "no pain" and the extreme right end "unbearable pain"); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and C reactive protein level.

    Time frame: Baseline to Week 52

  14. Correlation of Magnetic Resonance Imaging Assessments and Clinical Outcome Measures

    Correlation coefficients of magnetic resonance imaging erosion, synovitis, and osteitis scores and clinical outcome measures of swollen joint count (SJC), tender joint count (TJC), C-reactive protein level (CRP), erythrocyte sedimentation rate (ESR), a participant's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (GH), Disease Activity Score 28-C-reactive protein (DAS28-CRP), and Disease Activity Score 28-erythrocyte sedimentation rate (DAS28-ESR) are reported. Not all of these variables were specified as primary or secondary Outcome Measures in the study protocol and were not individually analyzed.

    Time frame: Baseline to Week 52

  15. Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Weeks 24 and 52

    The HAQ-DI assesses how well the patient is able to perform 8 activities: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. The patient answers 20 questions with 1 of 4 responses with the past week as the time frame: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The highest score for any question in a category determines the category score. The total score ranges from 0 (no disability) to 3 (completely disabled). A negative change score indicates improvement.

    Time frame: Baseline to Week 52

  16. Adverse Events (AEs), Laboratory Parameters, C-reactive Protein, ESR.

    Time frame: Throughout study

07

Results

Posted Apr 10, 2015

Participant flow

Double-blind Treatment Phase
Participant flow — Double-blind Treatment Phase
MilestoneRituximab 500 mgRituximab 1000 mgPlacebo
Started626063
Treated626063
Completed595649
Not completed3414
Extension Phase
Participant flow — Extension Phase
MilestoneRituximab 500 mgRituximab 1000 mgPlacebo
Started535043
Completed494940
Not completed413
Safety Follow-up Phase
Participant flow — Safety Follow-up Phase
MilestoneRituximab 500 mgRituximab 1000 mgPlacebo
Started575454
Completed1198
Not completed464546

Outcome measures

PrimaryChange in Magnetic Resonance Imaging (MRI) Erosion Score From Baseline to Week 24

The erosion score was determined according to the Outcome Measures in Rheumatology (OMERACT) rheumatoid arthritis MRI scoring (RAMRIS) system in magnetic resonance images with and without gadolinium of 15 anatomical locations in each wrist and 10 locations in each hand in the hand and wrist with the most arthritic activity. If there was no difference in disease activity between the hands, the dominant hand was used. Images were assessed by 2 experienced blinded musculoskeletal radiologists. Each location was scored in 0.5 increments from 0 to 10 with each integer unit increment representing a 10% loss of articular bone using the following scale. 0.0=normal, no erosion; 0.5=1-5% erosion; 1.0=6-10% erosion; 1.5=11-15% erosion; 2.0=16-20% erosion; etc, up to 10.0=96-100% erosion. The individual scores were summed and normalized to a range of 0 to 100 with a higher score indicating more erosion. A negative change score indicates improvement.

Time frame:
Baseline to Week 24
Reported as:
Mean · Units on a scale
Change in Magnetic Resonance Imaging (MRI) Erosion Score From Baseline to Week 24
Units on a scaleRituximab 500 mgRituximab 1000 mgPlacebo
Change in Magnetic Resonance Imaging (MRI) Erosion Score From Baseline to Week 240.13 ± 2.2580.39 ± 1.8071.33 ± 2.235
SecondaryChange in Magnetic Resonance Imaging (MRI) Erosion Score From Baseline to Weeks 12 and 52

The erosion score was determined according to the Outcome Measures in Rheumatology (OMERACT) rheumatoid arthritis MRI scoring (RAMRIS) system in magnetic resonance images with and without gadolinium of 15 anatomical locations in each wrist and 10 locations in each hand in the hand and wrist with the most arthritic activity. If there was no difference in disease activity between the hands, the dominant hand was used. Images were assessed by 2 experienced blinded musculoskeletal radiologists. Each location was scored in 0.5 increments from 0 to 10 with each integer unit increment representing a 10% loss of articular bone using the following scale. 0.0=normal, no erosion; 0.5=1-5% erosion; 1.0=6-10% erosion; 1.5=11-15% erosion; 2.0=16-20% erosion; etc, up to 10.0=96-100% erosion. The individual scores were summed and normalized to a range of 0 to 100 with a higher score indicating more erosion. A negative change score indicates improvement.

Time frame:
Baseline to Week 52
Reported as:
Mean · Units on a scale
Change in Magnetic Resonance Imaging (MRI) Erosion Score From Baseline to Weeks 12 and 52
Units on a scaleRituximab 500 mgRituximab 1000 mgPlacebo
Week 12 (n = 58, 58, 56)0.42 ± 1.6930.13 ± 1.7640.33 ± 4.122
Week 52 (n = 56, 57, 58)0.11 ± 2.623-0.30 ± 2.3723.02 ± 4.456
SecondaryChange in Magnetic Resonance Imaging (MRI) Synovitis Score From Baseline to Weeks 12, 24, and Week 52

The synovitis score was determined according to the Outcome Measures in Rheumatology (OMERACT) rheumatoid arthritis MRI scoring (RAMRIS) system in magnetic resonance images of 3 wrist regions and 5 metacarpophalangeal joints in the hand and wrist with the most arthritic activity. If there was no difference in disease activity between the hands, the dominant hand was used. Images were assessed by 2 experienced blinded musculoskeletal radiologists. Each location was scored in 0.5 increments from 0 to 3 with each integer unit increment representing a 33% enhancement of the maximum volume of enhancing tissue in the synovial compartment using the following scale: 0.0=normal, no synovitis; 0.5=1-17% estimated volume of enhancement; 1.0=18-33%; 1.5=34-50%; 2.0=51-67%; 2.5=68-83%; 3.0=84-100% estimated volume of enhancement. The individual scores were summed and normalized to a range of 0 to 100 with a higher score indicating more synovitis. A negative change score indicates improvement.

Time frame:
Baseline to Week 52
Reported as:
Mean · Units on a scale
Change in Magnetic Resonance Imaging (MRI) Synovitis Score From Baseline to Weeks 12, 24, and Week 52
Units on a scaleRituximab 500 mgRituximab 1000 mgPlacebo
Week 12 (n = 58, 58, 56)-0.50 ± 1.701-1.15 ± 1.866-0.22 ± 2.050
Week 24 (n = 61, 59, 59)-1.14 ± 1.923-1.81 ± 2.2890.20 ± 2.257
Week 52 (n = 61, 59, 59)-2.03 ± 2.562-2.73 ± 3.120-0.01 ± 2.700
SecondaryChange in Magnetic Resonance Imaging (MRI) Osteitis Score From Baseline to Weeks 12, 24, and Week 52

The osteitis score was determined according to the Outcome Measures in Rheumatology (OMERACT) rheumatoid arthritis MRI scoring (RAMRIS) system in magnetic resonance images of 15 anatomical locations in each wrist and 10 locations in each hand in the hand and wrist with the most arthritic activity. If there was no difference in disease activity between the hands, the dominant hand was used. Each location was scored in 0.5 increments from 0 to 3 with each integer unit increment representing a 33% increase in the volume of the peripheral 1 cm of original (eroded + residual) articular bone using the following scale: 0.0=normal, no osteitis; 0.5=1-17% involvement of original articular bone; 1.0=18-33%; 1.5=34-50%; 2.0=51-67%; 2.5=68-83%; 3.0=84-100% involvement of original articular bone. The individual scores were summed and normalized to a range of 0 to 100 with a higher score indicating more synovitis. A negative change score indicates improvement.

Time frame:
Baseline to Week 52
Reported as:
Mean · Units on a scale
Change in Magnetic Resonance Imaging (MRI) Osteitis Score From Baseline to Weeks 12, 24, and Week 52
Units on a scaleRituximab 500 mgRituximab 1000 mgPlacebo
Week 12 (n = 58, 58, 56)-2.11 ± 5.049-1.88 ± 5.366-0.14 ± 3.940
Week 24 (n = 61, 59, 59)-2.91 ± 5.687-2.86 ± 5.9760.07 ± 5.574
Week 52 (n = 61, 59, 59)-4.75 ± 7.413-3.83 ± 6.255-0.22 ± 6.390
SecondaryPercentage of Participants With no Newly Eroded Joints at Weeks 24 and 52

No newly eroded joints was defined as no new erosions in joints which were scored 0 at baseline. The erosion score was determined according to the Outcome Measures in Rheumatology (OMERACT) rheumatoid arthritis MRI scoring (RAMRIS) system in magnetic resonance images with and without gadolinium of 15 anatomical locations in each wrist and 10 locations in each hand in the hand and wrist with the most arthritic activity. If there was no difference in disease activity between the hands, the dominant hand was used. Images were assessed by 2 experienced blinded musculoskeletal radiologists. Each location was scored in 0.5 increments from 0 to 10 with each integer unit increment representing a 10% loss of articular bone using the following scale. 0.0=normal, no erosion; 0.5=1-5% erosion; 1.0=6-10% erosion; 1.5=11-15% erosion; 2.0=16-20% erosion; etc, up to 10.0=96-100% erosion.

Time frame:
Baseline to Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With no Newly Eroded Joints at Weeks 24 and 52
Percentage of participantsRituximab 500 mgRituximab 1000 mgPlacebo
Week 2477.473.355.5
Week 5277.44060.3
SecondaryPercentage of Participants With no Progression/no Worsening in Bone Erosion at Weeks 24 and 52

There were 2 definitions of no progression/no worsening in bone erosion. A participant met the criterion for definition 1 when there was a change in the magnetic resonance imaging erosion score ≤ 0. A participant met the criteria for definition 2 when there was either (1) no change from Baseline in the MRI erosion score, (2) an increase in erosion score and the size of the increase in score was smaller than the smallest detectable change, or (3) a drop in the erosion score. The erosion score was determined according to the Outcome Measures in Rheumatology (OMERACT) rheumatoid arthritis MRI scoring (RAMRIS) system in magnetic resonance images with and without gadolinium of 15 anatomical locations in each wrist and 10 locations in each hand in the hand and wrist with the most arthritic activity. If there was no difference in disease activity between the hands, the dominant hand was used. Images were assessed by 2 experienced blinded musculoskeletal radiologists.

Time frame:
Baseline to Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With no Progression/no Worsening in Bone Erosion at Weeks 24 and 52
Percentage of participantsRituximab 500 mgRituximab 1000 mgPlacebo
Week 24 (Definition 1)50.051.733.3
Week 24 (Definition 2)88.796.781.0
Week 52 (Definition 1)48.455.027.0
Week 52 (Definition 2)85.593.355.6
SecondaryPercentage of Participants With Improvement in Synovitis at Weeks 24 and 52

There were 2 definitions of improvement in synovitis. A participant met the criterion for definition 1 when there was a drop in the magnetic resonance imaging synovitis score from Baseline \> 0.5. A participant met the criterion for definition 2 when there was a drop in the magnetic resonance imaging synovitis score from Baseline \> than the smallest detectable change. The synovitis score was determined according to the Outcome Measures in Rheumatology (OMERACT) rheumatoid arthritis MRI (RAMRIS) scoring system in magnetic resonance images with and without gadolinium of 15 anatomical locations in each wrist and 10 locations in each hand in the hand and wrist with the most arthritic activity. If there was no difference in disease activity between the hands, the dominant hand was used. Images were assessed by 2 experienced blinded musculoskeletal radiologists.

Time frame:
Baseline to Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With Improvement in Synovitis at Weeks 24 and 52
Percentage of participantsRituximab 500 mgRituximab 1000 mgPlacebo
Week 24 (Definition 1)41.956.722.2
Week 24 (Definition 2)41.956.722.2
Week 52 (Definition 1)54.860.025.4
Week 52 (Definition 2)54.860.025.4
SecondaryPercentage of Participants With Improvement in Osteitis at Weeks 24 and 52

There were 2 definitions of improvement in osteitis. A participant met the criterion for definition 1 when there was a drop in the magnetic resonance imaging osteitis score from Baseline \> 0.5. A participant met the criterion for definition 2 when there was a drop in the magnetic resonance imaging osteitis score from Baseline \> than the smallest detectable change. The osteitis score was determined according to the Outcome Measures in Rheumatology (OMERACT) rheumatoid arthritis MRI (RAMRIS) scoring system in magnetic resonance images with and without gadolinium of 15 anatomical locations in each wrist and 10 locations in each hand in the hand and wrist with the most arthritic activity. If there was no difference in disease activity between the hands, the dominant hand was used. Images were assessed by 2 experienced blinded musculoskeletal radiologists.

Time frame:
Baseline to Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With Improvement in Osteitis at Weeks 24 and 52
Percentage of participantsRituximab 500 mgRituximab 1000 mgPlacebo
Week 24 (Definition 1)50.051.722.2
Week 24 (Definition 2)50.051.722.2
Week 52 (Definition 1)58.151.727.0
Week 52 (Definition 2)58.151.727.0
SecondaryChange From Baseline in the Disease Activity Score 28 (DAS28) at Weeks 24 and 52

The DAS28 is a combined index for measuring disease activity in rheumatic arthritis (RA) and includes swollen and tender joint counts, C-reactive protein level (CRP), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(CRO)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints, GH = a participant's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity \[symptom-free and no arthritis symptoms\], right end = maximum disease activity \[maximum arthritis disease activity\]). The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. A negative change score indicates improvement.

Time frame:
Baseline to Week 52
Reported as:
Mean · Units on a scale
Change From Baseline in the Disease Activity Score 28 (DAS28) at Weeks 24 and 52
Units on a scaleRituximab 500 mgRituximab 1000 mgPlacebo
Week 24 (n = 63, 62, 59)-1.714 ± 1.2204-1.683 ± 1.0158-0.752 ± 1.1834
Week 52 (n = 63, 62, 59)-2.055 ± 1.1844-1.801 ± 1.0443-0.747 ± 1.2557
SecondaryPercentage of Participants With European League Against Rheumatism (EULAR) Good, Moderate, or no Response at Weeks 24 and 52

Change of the DAS28 score from Baseline was used to determine the EULAR responses. For a post-Baseline score ≤ 3.2, a change from Baseline of \< -1.2 was a good response, \< -0.6 to ≥ -1.2 was a moderate response, and ≥ -0.6 was no response. For a post-Baseline score \> 3.2 to ≤ 5.1, a change from Baseline of \< -0.6 was a moderate response and ≥ -0.6 was no response. For a post-Baseline score \> 5.1, a change from Baseline \< -1.2 was a moderate response and ≥ -1.2 was no response. A good response could not be achieved for post-Baseline scores \> 3.2. DAS28=(0.56×√(TJC28))+(0.28×√(SJC28))+(0.7×log(CRP))+(0.014×GH), where TJC28=tender joint count (JC) and SJC28=swollen JC (28 joints), GH=a participant's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end=no disease activity, right end=maximum disease activity), and CRP=C-reactive protein level. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.

Time frame:
Baseline to Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With European League Against Rheumatism (EULAR) Good, Moderate, or no Response at Weeks 24 and 52
Percentage of participantsRituximab 500 mgRituximab 1000 mgPlacebo
Week 24 - No response33.922.058.7
Week 24 - Moderate response37.142.422.2
Week 24 - Good response29.035.619.0
Week 52 (n = 63, 62, 59) - No response21.013.660.3
Week 52 (n = 63, 62, 59) - Moderate response45.249.231.7
Week 52 (n = 63, 62, 59) - Good response33.937.37.9
SecondaryPercentage of Participants With Low Disease Activity (Disease Activity Score 28 [DAS28] ≤ 3.2) at Weeks 24 and 52

The percentage of participants who had low rheumatic arthritis disease activity at Weeks 24 and 52, as measured by a DAS28 score ≤ 3.2, is reported. DAS28 is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(CRO)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints, GH = a participant's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity \[symptom-free and no arthritis symptoms\], right end = maximum disease activity \[maximum arthritis disease activity\]), and CRP = C-reactive protein level. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.

Time frame:
Baseline to Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With Low Disease Activity (Disease Activity Score 28 [DAS28] ≤ 3.2) at Weeks 24 and 52
Percentage of participantsRituximab 500 mgRituximab 1000 mgPlacebo
Week 2433.936.719.0
Week 5237.138.39.5
SecondaryPercentage of Participants in Remission Response (Disease Activity Score 28 [DAS28] < 2.6) at Weeks 24 and 52

The percentage of participants in remission of their rheumatic arthritis at Weeks 24 and 52, as measured by a DAS28 score \< 2.6, is reported. DAS28 is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(CRO)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints, GH = a participant's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity \[symptom-free and no arthritis symptoms\], right end = maximum disease activity \[maximum arthritis disease activity\]), and CRP = C-reactive protein level. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.

Time frame:
Baseline to Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants in Remission Response (Disease Activity Score 28 [DAS28] < 2.6) at Weeks 24 and 52
Percentage of participantsRituximab 500 mgRituximab 1000 mgPlacebo
Week 2421.028.312.7
Week 5225.825.07.9
SecondaryPercentage of Participants With an Improvement of at Least 20%, 50%, or 70% in the American College of Rheumatology (ACR) Score (ACR20/50/70) From Baseline at Weeks 24 and 52

Improvement must be seen in tender and swollen joint counts (28 assessed joints; Joints were evaluated and classified as swollen or not swollen and tender or not tender based on pressure and joint manipulation upon physical examination) and in at least 3

Time frame:
Baseline to Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With an Improvement of at Least 20%, 50%, or 70% in the American College of Rheumatology (ACR) Score (ACR20/50/70) From Baseline at Weeks 24 and 52
Percentage of participantsRituximab 500 mgRituximab 1000 mgPlacebo
Week 24 - ACR20 response51.651.728.6
Week 24 - ACR50 response24.226.711.1
Week 24 - ACR70 response11.38.31.6
Week 52 - ACR20 response67.768.328.6
Week 52 - ACR50 response37.135.014.3
Week 52 - ACR70 response17.716.76.3
SecondaryPercentage of Participants Achieving a Major Clinical Response at Week 52

A major clinical response was defined as an improvement of at least 70% in the American College of Rheumatology score from Baseline at Week 52. Improvement must be seen in tender and swollen joint counts (28 assessed joints) and in at least 3 of the following 5 parameters: Separate participant and physician assessments of participant disease activity in the previous 24 hours on a visual analog scale (VAS, the extreme left end of the line "no disease activity" \[symptom-free and no arthritis symptoms\] and the extreme right end "maximum disease activity"); participant assessment of pain in previous the 24 hours on a VAS (extreme left end of the line "no pain" and the extreme right end "unbearable pain"); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and C reactive protein level.

Time frame:
Baseline to Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a Major Clinical Response at Week 52
Percentage of participantsRituximab 500 mgRituximab 1000 mgPlacebo
Percentage of Participants Achieving a Major Clinical Response at Week 526.56.71.6
SecondaryCorrelation of Magnetic Resonance Imaging Assessments and Clinical Outcome Measures

Correlation coefficients of magnetic resonance imaging erosion, synovitis, and osteitis scores and clinical outcome measures of swollen joint count (SJC), tender joint count (TJC), C-reactive protein level (CRP), erythrocyte sedimentation rate (ESR), a participant's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (GH), Disease Activity Score 28-C-reactive protein (DAS28-CRP), and Disease Activity Score 28-erythrocyte sedimentation rate (DAS28-ESR) are reported. Not all of these variables were specified as primary or secondary Outcome Measures in the study protocol and were not individually analyzed.

Time frame:
Baseline to Week 52
Reported as:
Number · Correlation coefficient
Correlation of Magnetic Resonance Imaging Assessments and Clinical Outcome Measures
Correlation coefficientRituximab 500 mgRituximab 1000 mgPlacebo
Erosion score and SJC - Week 240.3410.4250.446
Erosion score and SJC - Week 520.2870.2340.355
Synovitis score and SJC - Week 240.3290.3890.566
Synovitis score and SJC - Week 520.1680.1880.574
Osteitis score and SJC - Week 240.4070.3540.370
Osteitis score and SJC - Week 520.2650.1920.398
Erosion score and TJC - Week 240.3640.1150.298
Erosion score and TJC - Week 520.2750.0670.425
Synovitis score and TJC - Week 240.3360.1740.282
Synovitis score and TJC - Week 520.1420.0360.421
Osteitis score and TJC - Week 240.3550.1180.288
Osteitis score and TJC - Week 520.2450.0480.371
Erosion score and CRP - Week 240.185-0.0240.006
Erosion score and CRP - Week 520.0550.0980.352
Synovitis score and CRP - Week 240.0300.0900.192
Synovitis score and CRP - Week 52-0.0770.0850.311
Osteitis score and CRP - Week 24-0.031-0.0570.040
Osteitis score and CRP - Week 520.005-0.0100.119
Erosion score and ESR - Week 240.3210.1360.197
Erosion score and ESR - Week 520.1270.1880.314
Synovitis score and ESR - Week 240.1820.2140.358
Synovitis score and ESR - Week 520.1850.2480.360
Osteitis score and ESR - Week 240.0440.0430.148
Osteitis score and ESR - Week 52-0.0410.1160.205
Erosion score and GH - Week 240.2060.0430.326
Erosion score and GH - Week 520.063-0.0090.316
Synovitis score and GH - Week 240.1860.2210.206
Synovitis score and GH - Week 52-0.026-0.0370.286
Osteitis score and GH - Week 240.2740.1220.205
Osteitis score and GH - Week 520.1060.0520.136
Erosion score and DAS28-CRP - Week 240.4200.1980.457
Erosion score and DAS28-CRP - Week 520.2380.1270.498
Synovitis score and DAS28-CRP - Week 240.3930.3490.437
Synovitis score and DAS28-CRP - Week 520.1490.1500.500
Osteitis score and DAS28-CRP - Week 240.3800.2090.351
Osteitis score and DAS28-CRP - Week 520.1390.1430.356
Erosion score and DAS28-ESR - Week 240.4290.2550.439
Erosion score and DAS28-ESR - Week 520.2440.1800.473
Synovitis score and DAS28-ESR - Week 240.3980.3320.438
Synovitis score and DAS28-ESR - Week 520.1980.1470.514
Osteitis score and DAS28-ESR - Week 240.3530.2310.353
Osteitis score and DAS28-ESR - Week 520.1080.1720.356
SecondaryChange From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Weeks 24 and 52

The HAQ-DI assesses how well the patient is able to perform 8 activities: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. The patient answers 20 questions with 1 of 4 responses with the past week as the time frame: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The highest score for any question in a category determines the category score. The total score ranges from 0 (no disability) to 3 (completely disabled). A negative change score indicates improvement.

Time frame:
Baseline to Week 52
Reported as:
Mean · Units on a scale
Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Weeks 24 and 52
Units on a scaleRituximab 500 mgRituximab 1000 mgPlacebo
Week 24 (n = 63, 62, 59)-0.425 ± 0.5606-0.439 ± 0.4770-0.194 ± 0.5849
Week 52 (n = 63, 62, 59)-0.520 ± 0.5873-0.417 ± 0.4450-0.177 ± 0.5943
SecondaryAdverse Events (AEs), Laboratory Parameters, C-reactive Protein, ESR.
Time frame:
Throughout study

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rituximab 500 mg - Double-blind Treatment Phase—3/62 (4.8%)24/62 (38.7%)
Rituximab 1000 mg - Double-blind Treatment Phase—4/60 (6.7%)24/60 (40%)
Placebo - Double-blind Treatment Phase—5/63 (7.9%)20/63 (31.7%)
Rituximab 500 mg - Extension Phase—3/50 (6%)0/50 (0%)
Rituximab 1000 mg - Extension Phase—5/47 (10.6%)0/47 (0%)
Placebo - Extension Phase—2/41 (4.9%)0/41 (0%)
Rituximab 500 mg - Safety Follow-up Phase—0/57 (0%)0/57 (0%)
Rituximab 1000 mg - Safety Follow-up Phase—1/54 (1.9%)0/54 (0%)
Placebo - Safety Follow-up Phase—0/54 (0%)0/54 (0%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventRituximab 500 mg - Double-blind Treatment PhaseRituximab 1000 mg - Double-blind Treatment PhasePlacebo - Double-blind Treatment PhaseRituximab 500 mg - Extension PhaseRituximab 1000 mg - Extension PhasePlacebo - Extension PhaseRituximab 500 mg - Safety Follow-up PhaseRituximab 1000 mg - Safety Follow-up PhasePlacebo - Safety Follow-up Phase
Rheumatoid arthritisMusculoskeletal and connective tissue disorders0/620/602/630/500/470/410/570/540/54
ErysipelasInfections and infestations0/620/600/630/500/471/410/570/540/54
Cholecystitis acuteHepatobiliary disorders0/620/600/630/500/471/410/570/540/54
CholelithiasisHepatobiliary disorders0/620/600/630/500/471/410/570/540/54
Respiratory tract infection viralInfections and infestations0/620/600/630/501/470/410/570/540/54
Back painMusculoskeletal and connective tissue disorders0/620/600/630/501/470/410/570/540/54
Knee deformityMusculoskeletal and connective tissue disorders0/620/600/630/501/470/410/570/540/54
Colorectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/620/600/630/501/470/410/570/540/54
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/620/600/630/501/470/410/570/540/54
Breast massReproductive system and breast disorders0/620/600/630/501/470/410/570/540/54
Most frequent other events
Most frequent other events
EventRituximab 500 mg - Double-blind Treatment PhaseRituximab 1000 mg - Double-blind Treatment PhasePlacebo - Double-blind Treatment PhaseRituximab 500 mg - Extension PhaseRituximab 1000 mg - Extension PhasePlacebo - Extension PhaseRituximab 500 mg - Safety Follow-up PhaseRituximab 1000 mg - Safety Follow-up PhasePlacebo - Safety Follow-up Phase
Rheumatoid arthritisImmune system disorders2/621/606/630/500/470/410/570/540/54
BronchitisInfections and infestations4/625/602/630/500/470/410/570/540/54
Back painMusculoskeletal and connective tissue disorders1/624/601/630/500/470/410/570/540/54
Upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders2/624/601/630/500/470/410/570/540/54
ArthralgiaMusculoskeletal and connective tissue disorders4/620/601/630/500/470/410/570/540/54
HeadacheNervous system disorders4/620/601/630/500/470/410/570/540/54
Viral infectionInfections and infestations4/623/602/630/500/470/410/570/540/54
HypertensionVascular disorders0/621/604/630/500/470/410/570/540/54
NasopharyngitisRespiratory, thoracic and mediastinal disorders2/623/602/630/500/470/410/570/540/54
Oral herpesInfections and infestations1/623/600/630/500/470/410/570/540/54

Baseline characteristics

Safety population: All participants who received any part of an infusion of the study drug during the main study.

Age, Continuous
Age, Continuous(years)Rituximab 500 mgRituximab 1000 mgPlaceboTotal
Mean48.7 ± 11.1050.7 ± 11.6550.3 ± 11.9449.9 ± 11.54
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab 500 mgRituximab 1000 mgPlaceboTotal
Female455048143
Male17101542
08

Study locations

60 sites
  • Buenos Aires, C1280AEB, Argentina
  • Goiania, GO 74110010, Brazil
  • Curtiba, PR 80030-110, Brazil
  • Porto Alegre, RS 90610-000, Brazil
  • Sao Paulo, SP 04023-900, Brazil
  • Winnipeg, Manitoba R3E0W3, Canada
  • St John's, Newfoundland and Labrador A1A 5E8, Canada
  • Ottawa, Ontario K1H 1A2, Canada
  • Ottawa, Ontario K2G 6E2, Canada
  • Toronto, Ontario M4N 3M5, Canada
  • Montreal, Quebec H1T 2M4, Canada
  • Montreal, Quebec H2L 1S6, Canada
  • Montreal, Quebec H3Z 2Z3, Canada
  • Quebec City, Quebec G1V 3M7, Canada
  • Saskatoon, Saskatchewan S7M 0Z9, Canada
  • Brno, 625 00, Czech Republic
  • Ceské Budejovice, 370 01, Czech Republic
  • Praha, 128 50, Czech Republic
  • Hillerod, 3400, Denmark
  • Hvidovre, 2650, Denmark
  • København, 2100, Denmark
  • Tallinn, 11312, Estonia
  • Tallinn, 13419, Estonia
  • Montpellier, 34295, France
  • Nice, 06202, France
  • Orleans, 45032, France
  • Toulouse, 31059, France
  • Bad Aibling, 83043, Germany
  • Berlin, 10117, Germany
  • Dresden, 01307, Germany
  • Erlangen, 91054, Germany
  • Halle, 06120, Germany
  • Hannover, 30625, Germany
  • Athens, 115 27, Greece
  • Patras, 265 04, Greece
  • Thessaloniki, 54636, Greece
  • Riga, 1002, Latvia
  • Riga, 1038, Latvia
  • Vilnius, LT-08661, Lithuania
  • Amsterdam, 1105 AZ, Netherlands
  • Oslo, 0370, Norway
  • Bucharest, 020475, Romania
  • Cluj-napoca, 400006, Romania
  • Kazan, 420097, Russian Federation
  • Moscow, 115522, Russian Federation
  • Saint-Petersburg, 195067, Russian Federation
  • Voronezh, 394066, Russian Federation
  • Belgrade, 11000, Serbia
  • Niska Banja, 18250, Serbia
  • Barcelona, 08003, Spain
  • Barcelona, 08907, Spain
  • Madrid, 28046, Spain
  • Malaga, 29010, Spain
  • Sevilla, 41009, Spain
  • Valencia, 46017, Spain
  • Bern, 3010, Switzerland
  • Adana, 01330, Turkey
  • Ankara, 06018, Turkey
  • Istanbul, 34098, Turkey
  • Izmir, 35100, Turkey
09

References and documents

Publications

  • Peterfy C, Emery P, Tak PP, Ostergaard M, DiCarlo J, Otsa K, Navarro Sarabia F, Pavelka K, Bagnard MA, Gylvin LH, Bernasconi C, Gabriele A. MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study. Ann Rheum Dis. 2016 Jan;75(1):170-7. doi: 10.1136/annrheumdis-2014-206015. Epub 2014 Oct 29. PubMed 25355728 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Nov 2009 and a completion of May 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2015, 5 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2007
First posted
Dec 21, 2007
Start
Nov 2007
Primary completionActual
Nov 2009
CompletionActual
May 2013
Results first posted
Apr 10, 2015
Last update
Apr 10, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00578305
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 21, 2007
Start date
Nov 2007
Primary completion
Nov 2009
Completion
May 2013
Results posted
Apr 10, 2015
Last update
Apr 10, 2015

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion